吡拉米司特
吡拉米司特 性质
| 沸点 | 447.8±45.0 °C(Predicted) |
|---|---|
| 密度 | 1.370 |
| 储存条件 | 2-8°C |
| 溶解度 | 在DMSO中的溶解度为20mg/mL，澄清 |
| 酸度系数(pKa) | 10.10±0.70(Predicted) |
| 形态 | 粉末 |
| 颜色 | 白色至米色 |
| InChI | 1S/C18H18Cl2N2O3/c1-24-15-7-6-11(8-16(15)25-12-4-2-3-5-12)18(23)22-17-13(19)9-21-10-14(17)20/h6-10,12H,2-5H2,1H3,(H,21,22,23) |
| InChIKey | RRRUXBQSQLKHEL-UHFFFAOYSA-N |
| SMILES | Clc1cncc(c1NC(=O)c2cc(c(cc2)OC)OC3CCCC3)Cl |
吡拉米司特 用途与合成方法
|
PDE4 16 nM (IC 50 , in pig aorta) |
PDE4 2 nM (IC 50 , in eosinophil soluble) |
PDE1 >100 μM (IC 50 ) |
PDE2 40 μM (IC 50 ) |
PDE3 >100 μM (IC 50 ) |
PDE5 14 μM (IC 50 ) |
Piclamilast (RP 73401, 1 μM, 30 min) significantly inhibits the changes in 23 genes via mechanisms involving AP-1 activation and c-Jun phosphorylation at Ser63.
Piclamilast (RP 73401) exhibits IC
50
values >100 μM, 40 μM, >100 μM, 14 μM for PDE1, PDE2, PDE3 and PDE5. Respectively.
RT-PCR
| Cell Line: | Human A549 type II lung epithelial cells. |
| Concentration: | 1 μM (H 2 O 2 200 μM). |
| Incubation Time: | 30 min. |
| Result: | Prevented H 2 O 2 -induced changes in gene expression levels in A549 cells. |
Cell Viability Assay
| Cell Line: | NB4 cells. |
| Concentration: | 30 μM. |
| Incubation Time: | 3 days. |
| Result: |
Exerted a significant enhancing effect on the induction of STAT1 observed in ATRA-treated NB4 cells.
Caused a significant increase in the number of cells expressing NBT-R activity. |
Piclamilast (RP 73401, 10 mg/kg, 30 min) alone does not affect the MST of leukemia-bearing animals. Piclamilast combined with ATRA (HY-14649) significantly more effective than ATRA alone in increasing the MST (40 days; interval 34–45 days) of leukemia-bearing animals.
| Animal Model: | SCID mice. |
| Dosage: | 10 mg/kg (combined with ATRA (HY-14649)). |
| Administration: | Injection daily. |
| Result: | Significantly more effective than ATRA alone in increasing the MST (40 days; interval 34–45 days) of leukemia-bearing animals. |
吡拉米司特 价格(试剂级)
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2026-09-15 | HY-12887 | 吡拉米司特 | 144035-83-6 | 1 mg | 490 |
| 2026-09-15 | HY-12887 | 吡拉米司特 | 144035-83-6 | 5 mg | 1200 |
